ESPR
Esperion Therapeutics, Inc.
Price Chart
Latest Quote
$3.15
-0.02 (-0.63%)
Current Price
| Previous Close | $3.17 |
| Open | $3.17 |
| Day High | $3.17 |
| Day Low | $3.15 |
| Volume | 17,496,865 |
Stock Information
| Shares Outstanding | 257.69M |
| Total Debt | $543.81M |
| Cash Equivalents | $156.16M |
| Revenue | $418.24M |
| Net Income | $-7.42M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | $811.73M |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $1.20B |
| Sales | $418.24M |
| Income | $-7.42M |
| Book/sh | $-1.23 |
| Cash/sh | $0.61 |
| Employees | 294 |
Financial Ratios
| Quick Ratio | 0.96 |
| Current Ratio | 1.53 |
Returns & Margins
| ROA | 12.04% |
| Gross Margin | 57.79% |
| Operating Margin | -8.22% |
| Profit Margin | -1.77% |
Ownership
| Insider Ownership | 0.90% |
| Institutional Ownership | 78.09% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 10.79 |
| P/S | 1.94 |
| P/B | -2.56 |
Analyst Data
| Recommendation | none |
| Target Price | $3.19 |
Technical Indicators
| SMA20 | $3.14 |
| SMA50 | $2.78 |
| SMA200 | $3.02 |
| RSI | 60.00 |
| ATR | 0.0143 |
| Shares Float | 234.36M |
| Short Float | 7.39% |
| Short Ratio | 0.95 |
| Volatility | 1.07 |
| Rel Volume | 1.68 |
Performance History
| Week | +0.00% |
| Month | +0.64% |
| Quarter | +21.15% |
| 6 Months | -15.09% |
| YTD | -15.09% |
| Year | +188.99% |
| 3 Years | +148.03% |
| 5 Years | -88.05% |
| 10 Years | -81.83% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $3.15 | 17,496,900 |
| 2026-06-17 | $3.17 | 16,154,900 |
| 2026-06-16 | $3.16 | 7,851,800 |
| 2026-06-15 | $3.15 | 8,827,400 |
| 2026-06-12 | $3.15 | 11,225,600 |
| 2026-06-11 | $3.15 | 9,844,800 |
| 2026-06-10 | $3.14 | 7,085,000 |
| 2026-06-09 | $3.14 | 7,210,200 |
| 2026-06-08 | $3.15 | 11,339,000 |
| 2026-06-05 | $3.13 | 8,408,800 |
| 2026-06-04 | $3.13 | 8,810,500 |
| 2026-06-03 | $3.14 | 25,112,900 |
| 2026-06-02 | $3.14 | 14,043,700 |
| 2026-06-01 | $3.13 | 18,703,900 |
| 2026-05-29 | $3.13 | 5,309,700 |
| 2026-05-28 | $3.13 | 5,873,400 |
| 2026-05-27 | $3.13 | 6,302,400 |
| 2026-05-26 | $3.12 | 6,813,100 |
| 2026-05-22 | $3.13 | 6,695,100 |
| 2026-05-21 | $3.13 | 4,932,100 |
| 2026-05-20 | $3.13 | 7,812,600 |
| 2026-05-19 | $3.13 | 6,963,800 |
About Esperion Therapeutics, Inc.
Esperion Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia cardiovascular disease who require additional lowering of LDL-C. Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. It has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was formerly known as HDL Therapeutics, Inc. and changed its name to Esperion Therapeutics, Inc. in May 2008. The company was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
đ° Latest News
Why Is Altimmune (ALT) Down 11.3% Since Last Earnings Report?
Zacks âĸ 2026-06-12T15:30:02Z
Catalyst (CPRX) Up 0.6% Since Last Earnings Report: Can It Continue?
Zacks âĸ 2026-06-10T15:30:05Z
ESPR Stock Surges 44% in a Month: Here's What You Need to Know
Zacks âĸ 2026-05-14T14:44:00Z
ARCHIMED to acquire Esperion Therapeutics in $1.1 billion deal
Quartz âĸ 2026-05-01T15:13:53Z
Summitâs âself-inflictedâ stumble; Esperionâs take-private deal
BioPharma Dive âĸ 2026-05-01T12:28:00Z
Esperion Therapeutics Highlights 38% Revenue Growth, Enbumyst Launch Plan at Needham Conference
MarketBeat âĸ 2026-04-13T23:47:54Z
Esperion Therapeutics (ESPR) Down 10% Since Last Earnings Report: Can It Rebound?
Zacks âĸ 2026-04-09T15:30:03Z
Karyopharm Therapeutics (KPTI) Stock Jumps 6.9%: Will It Continue to Soar?
Zacks âĸ 2026-03-27T12:49:00Z
Esperion (ESPR) Highlights Inclusion of Bempedoic Acid in 2026 ACC/AHA Dyslipidemia Guidelines
Insider Monkey âĸ 2026-03-20T11:59:47Z
Esperion Therapeutics Touts 38% Revenue Growth, Corstasis Deal and 2026 Cash-Gen Path at Conference
MarketBeat âĸ 2026-03-16T00:03:26Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $129,224,000 | $68,601,000 | $43,267,000 | $26,967,000 |
| Cost Of Revenue | $129,224,000 | $68,601,000 | $43,267,000 | $26,967,000 |
| Total Revenue | $403,135,000 | $332,314,000 | $116,334,000 | $75,475,000 |
| Operating Revenue | $403,135,000 | $332,314,000 | $116,334,000 | $75,475,000 |
| Expenses | ||||
| Interest Expense | $84,604,000 | $59,251,000 | $58,976,000 | $56,810,000 |
| Total Expenses | $342,862,000 | $277,912,000 | $271,897,000 | $254,976,000 |
| Other Income Expense | $3,490,000 | $-46,896,000 | $5,291,000 | $2,652,000 |
| Other Non Operating Income Expenses | $3,490,000 | $8,022,000 | $5,291,000 | $2,652,000 |
| Net Non Operating Interest Income Expense | $-84,604,000 | $-59,251,000 | $-58,976,000 | $-56,810,000 |
| Interest Expense Non Operating | $84,604,000 | $59,251,000 | $58,976,000 | $56,810,000 |
| Operating Expense | $213,638,000 | $209,311,000 | $228,630,000 | $228,009,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-22,682,000 | $-51,745,000 | $-209,248,000 | $-233,659,000 |
| Net Interest Income | $-84,604,000 | $-59,251,000 | $-58,976,000 | $-56,810,000 |
| Normalized Income | $-22,682,000 | $3,173,000 | $-209,248,000 | $-233,659,000 |
| Net Income From Continuing And Discontinued Operation | $-22,682,000 | $-51,745,000 | $-209,248,000 | $-233,659,000 |
| Total Operating Income As Reported | $60,273,000 | $54,402,000 | $-155,563,000 | $-179,501,000 |
| Net Income Common Stockholders | $-22,682,000 | $-51,745,000 | $-209,248,000 | $-233,659,000 |
| Net Income | $-22,682,000 | $-51,745,000 | $-209,248,000 | $-233,659,000 |
| Net Income Including Noncontrolling Interests | $-22,682,000 | $-51,745,000 | $-209,248,000 | $-233,659,000 |
| Net Income Continuous Operations | $-22,682,000 | $-51,745,000 | $-209,248,000 | $-233,659,000 |
| Pretax Income | $-20,841,000 | $-51,745,000 | $-209,248,000 | $-233,659,000 |
| Special Income Charges | $0 | $-54,918,000 | $0 | $0 |
| Operating Income | $60,273,000 | $54,402,000 | $-155,563,000 | $-179,501,000 |
| Gross Profit | $273,911,000 | $263,713,000 | $73,067,000 | $48,508,000 |
| Per Share | ||||
| Diluted EPS | $-0.11 | $-0.28 | $-2.03 | $-3.52 |
| Basic EPS | $-0.11 | $-0.28 | $-2.03 | $-3.52 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $63,868,000 | $62,487,000 | $-150,108,000 | $-176,349,000 |
| Total Unusual Items | $0 | $-54,918,000 | $0 | $0 |
| Total Unusual Items Excluding Goodwill | $0 | $-54,918,000 | $0 | $0 |
| Reconciled Depreciation | $105,000 | $63,000 | $164,000 | $500,000 |
| EBITDA (Bullshit earnings) | $63,868,000 | $7,569,000 | $-150,108,000 | $-176,349,000 |
| EBIT | $63,763,000 | $7,506,000 | $-150,272,000 | $-176,849,000 |
| Diluted Average Shares | $207,865,080 | $187,181,856 | $103,106,616 | $66,407,242 |
| Basic Average Shares | $207,865,080 | $187,181,856 | $103,106,616 | $66,407,242 |
| Diluted NI Availto Com Stockholders | $-22,682,000 | $-51,745,000 | $-209,248,000 | $-233,659,000 |
| Tax Provision | $1,841,000 | $0 | $0 | - |
| Research And Development | $47,852,000 | $46,238,000 | $86,107,000 | $118,927,000 |
| Selling General And Administration | $165,786,000 | $163,073,000 | $142,523,000 | $109,082,000 |
| Other Special Charges | - | $54,918,000 | - | - |
Fetched: 2026-06-17
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-302,021,000 | $-388,778,000 | $-455,050,000 | $-323,834,000 |
| Total Assets | $465,886,000 | $343,821,000 | $205,796,000 | $247,939,000 |
| Total Non Current Assets | $3,316,000 | $5,823,000 | $4,731,000 | $1,256,000 |
| Goodwill And Other Intangible Assets | $56,000 | $56,000 | $56,000 | $56,000 |
| Current Assets | $462,570,000 | $337,998,000 | $201,065,000 | $246,683,000 |
| Other Current Assets | $4,496,000 | $4,155,000 | $4,507,000 | $9,866,000 |
| Prepaid Assets | $44,908,000 | $14,449,000 | $193,000 | $1,026,000 |
| Inventory | $105,124,000 | $94,491,000 | $65,623,000 | $35,201,000 |
| Receivables | $140,190,000 | $80,142,000 | $48,494,000 | $33,729,000 |
| Accounts Receivable | $140,190,000 | $80,142,000 | $48,494,000 | $33,729,000 |
| Cash Cash Equivalents And Short Term Investments | $167,852,000 | $144,761,000 | $82,248,000 | $166,861,000 |
| Cash And Cash Equivalents | $167,852,000 | $144,761,000 | $82,248,000 | $124,775,000 |
| Other Non Current Assets | - | - | - | - |
| Debt | ||||
| Net Debt | $81,627,000 | $147,530,000 | $179,348,000 | $135,124,000 |
| Total Debt | $252,234,000 | $297,602,000 | $266,169,000 | $260,948,000 |
| Long Term Debt And Capital Lease Obligation | $250,132,000 | $240,286,000 | $264,616,000 | $260,564,000 |
| Long Term Debt | $249,479,000 | $237,716,000 | $261,596,000 | $259,899,000 |
| Current Debt And Capital Lease Obligation | $2,102,000 | $57,316,000 | $1,553,000 | $384,000 |
| Current Debt | - | $54,575,000 | - | - |
| Other Current Borrowings | - | $54,575,000 | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $767,851,000 | $732,543,000 | $660,790,000 | $571,717,000 |
| Total Non Current Liabilities Net Minority Interest | $467,041,000 | $486,310,000 | $504,566,000 | $479,409,000 |
| Other Non Current Liabilities | $216,909,000 | $246,024,000 | $239,950,000 | $218,845,000 |
| Current Liabilities | $300,810,000 | $246,233,000 | $156,224,000 | $92,308,000 |
| Other Current Liabilities | $87,596,000 | $47,586,000 | - | - |
| Current Deferred Liabilities | $34,477,000 | $8,518,000 | $25,402,000 | $3,507,000 |
| Payables And Accrued Expenses | $164,695,000 | $120,074,000 | $118,500,000 | $79,364,000 |
| Interest Payable | $256,000 | $1,229,000 | $36,153,000 | $26,085,000 |
| Payables | $65,068,000 | $51,650,000 | $31,718,000 | $23,040,000 |
| Accounts Payable | $65,068,000 | $51,650,000 | $31,718,000 | $23,040,000 |
| Non Current Deferred Liabilities | - | - | - | $0 |
| Equity | ||||
| Common Stock Equity | $-301,965,000 | $-388,722,000 | $-454,994,000 | $-323,778,000 |
| Total Equity Gross Minority Interest | $-301,965,000 | $-388,722,000 | $-454,994,000 | $-323,778,000 |
| Stockholders Equity | $-301,965,000 | $-388,722,000 | $-454,994,000 | $-323,778,000 |
| Gains Losses Not Affecting Retained Earnings | $0 | $0 | $0 | $-2,000 |
| Retained Earnings | $-1,623,711,000 | $-1,601,029,000 | $-1,549,284,000 | $-1,340,036,000 |
| Other Equity Adjustments | - | - | - | $-2,000 |
| Other | ||||
| Treasury Shares Number | $1,994,198 | $1,994,198 | $1,994,198 | $1,994,198 |
| Ordinary Shares Number | $245,216,143 | $195,852,463 | $118,210,315 | $74,570,198 |
| Share Issued | $247,210,341 | $197,846,661 | $120,204,513 | $76,564,396 |
| Tangible Book Value | $-302,021,000 | $-388,778,000 | $-455,050,000 | $-323,834,000 |
| Invested Capital | $-52,486,000 | $-96,431,000 | $-193,398,000 | $-63,879,000 |
| Working Capital | $161,760,000 | $91,765,000 | $44,841,000 | $154,375,000 |
| Capital Lease Obligations | $2,755,000 | $5,311,000 | $4,573,000 | $1,049,000 |
| Total Capitalization | $-52,486,000 | $-151,006,000 | $-193,398,000 | $-63,879,000 |
| Treasury Stock | $54,998,000 | $54,998,000 | $54,998,000 | $54,998,000 |
| Additional Paid In Capital | $1,376,499,000 | $1,267,109,000 | $1,149,170,000 | $1,071,183,000 |
| Capital Stock | $245,000 | $196,000 | $118,000 | $75,000 |
| Common Stock | $245,000 | $196,000 | $118,000 | $75,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $653,000 | $2,570,000 | $3,020,000 | $665,000 |
| Current Deferred Revenue | $34,477,000 | $8,518,000 | $25,402,000 | $3,507,000 |
| Current Capital Lease Obligation | $2,102,000 | $2,741,000 | $1,553,000 | $384,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $11,940,000 | $12,739,000 | $10,769,000 | $9,053,000 |
| Current Accrued Expenses | $99,627,000 | $68,424,000 | $86,782,000 | $56,324,000 |
| Net PPE | $3,260,000 | $5,767,000 | $4,675,000 | $1,200,000 |
| Accumulated Depreciation | $-2,179,000 | $-2,074,000 | $-2,012,000 | $-2,551,000 |
| Gross PPE | $5,439,000 | $7,841,000 | $6,687,000 | $3,751,000 |
| Leases | $189,000 | $189,000 | $189,000 | $299,000 |
| Construction In Progress | $189,000 | $0 | - | - |
| Other Properties | $2,922,000 | $5,513,000 | $4,675,000 | $1,036,000 |
| Machinery Furniture Equipment | $2,139,000 | $2,139,000 | $1,823,000 | $2,416,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $1,823,000 | $6,196,000 | $2,005,000 | $2,095,000 |
| Work In Process | $4,534,000 | $3,711,000 | $1,728,000 | $6,548,000 |
| Raw Materials | $98,767,000 | $84,584,000 | $61,890,000 | $26,558,000 |
| Other Short Term Investments | - | - | $0 | $42,086,000 |
| Non Current Deferred Revenue | - | - | - | $0 |
Fetched: 2026-06-17
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-13,093,000 | $-23,971,000 | $-135,487,000 | $-174,827,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-13,093,000 | $-23,654,000 | $-135,487,000 | $-174,827,000 |
| Cash Flow From Continuing Operating Activities | $-13,093,000 | $-23,654,000 | $-135,487,000 | $-174,827,000 |
| Operating Gains Losses | - | $54,918,000 | - | - |
| Investing Activities | ||||
| Investing Cash Flow | $0 | $-317,000 | $42,500,000 | $8,104,000 |
| Cash Flow From Continuing Investing Activities | $0 | $-317,000 | $42,500,000 | $8,104,000 |
| Capital Expenditure | - | $-317,000 | - | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $88,004,000 | $91,185,000 | $56,876,000 | $90,849,000 |
| Financing Cash Flow | $36,184,000 | $86,484,000 | $50,460,000 | $32,606,000 |
| Cash Flow From Continuing Financing Activities | $36,184,000 | $86,484,000 | $50,460,000 | $32,606,000 |
| Net Other Financing Charges | $-7,256,000 | $-48,691,000 | $21,000 | $-50,219,000 |
| Cash Dividends Paid | $0 | $0 | $0 | $0 |
| Net Common Stock Issuance | $88,004,000 | $91,185,000 | $56,876,000 | $90,849,000 |
| Common Stock Issuance | $88,004,000 | $91,185,000 | $56,876,000 | $90,849,000 |
| Repurchase Of Capital Stock | - | - | - | - |
| Other | ||||
| Repayment Of Debt | $-54,912,000 | $-210,088,000 | $0 | $0 |
| Issuance Of Debt | $0 | $245,102,000 | $0 | $0 |
| Interest Paid Supplemental Data | $16,266,000 | $11,347,000 | $10,600,000 | - |
| Income Tax Paid Supplemental Data | $612,000 | $0 | $0 | - |
| End Cash Position | $167,852,000 | $144,761,000 | $82,248,000 | $124,775,000 |
| Beginning Cash Position | $144,761,000 | $82,248,000 | $124,775,000 | $258,892,000 |
| Changes In Cash | $23,091,000 | $62,513,000 | $-42,527,000 | $-134,117,000 |
| Interest Paid Cff | $0 | $-5,832,000 | $-15,506,000 | $-8,024,000 |
| Proceeds From Stock Option Exercised | $10,348,000 | $14,808,000 | $9,069,000 | $0 |
| Net Issuance Payments Of Debt | $-54,912,000 | $35,014,000 | $0 | $0 |
| Net Long Term Debt Issuance | $-54,912,000 | $35,014,000 | $0 | $0 |
| Long Term Debt Payments | $-54,912,000 | $-210,088,000 | $0 | $0 |
| Long Term Debt Issuance | $0 | $245,102,000 | $0 | $0 |
| Net Investment Purchase And Sale | $0 | $0 | $42,500,000 | $8,104,000 |
| Sale Of Investment | $0 | $0 | $42,500,000 | $68,001,000 |
| Net PPE Purchase And Sale | $0 | $-317,000 | $0 | $0 |
| Purchase Of PPE | $0 | $-317,000 | $0 | $0 |
| Change In Working Capital | $-14,642,000 | $-60,530,000 | $13,675,000 | $-3,373,000 |
| Change In Other Working Capital | $25,959,000 | $-16,884,000 | $21,895,000 | $-2,810,000 |
| Change In Other Current Liabilities | $8,739,000 | $0 | $0 | $0 |
| Change In Payables And Accrued Expense | $52,141,000 | $30,774,000 | $30,775,000 | $9,620,000 |
| Change In Accrued Expense | $31,223,000 | $18,342,000 | $22,097,000 | $4,017,000 |
| Change In Payable | $20,918,000 | $12,432,000 | $8,678,000 | $5,603,000 |
| Change In Account Payable | $20,918,000 | $12,432,000 | $8,678,000 | $5,603,000 |
| Change In Prepaid Assets | $-30,800,000 | $-13,904,000 | $6,192,000 | $1,419,000 |
| Change In Inventory | $-10,633,000 | $-28,868,000 | $-30,422,000 | $-807,000 |
| Change In Receivables | $-60,048,000 | $-31,648,000 | $-14,765,000 | $-10,795,000 |
| Changes In Account Receivables | $-60,048,000 | $-31,648,000 | $-14,765,000 | $-10,795,000 |
| Other Non Cash Items | $14,256,000 | $21,647,000 | $48,376,000 | $46,211,000 |
| Stock Based Compensation | $9,870,000 | $11,993,000 | $11,958,000 | $15,215,000 |
| Amortization Of Securities | $0 | $0 | $-412,000 | $279,000 |
| Depreciation Amortization Depletion | $105,000 | $63,000 | $164,000 | $500,000 |
| Depreciation And Amortization | $105,000 | $63,000 | $164,000 | $500,000 |
| Depreciation | $105,000 | $63,000 | $164,000 | $500,000 |
| Net Income From Continuing Operations | $-22,682,000 | $-51,745,000 | $-209,248,000 | $-233,659,000 |
| Purchase Of Investment | - | $0 | $0 | $-59,897,000 |
| Common Stock Payments | - | - | - | - |
| Net Intangibles Purchase And Sale | - | - | - | - |
| Purchase Of Intangibles | - | - | - | - |
Fetched: 2026-06-17